Phospho-Ataxin-1 (S776) Polyclonal Antibody

The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: aDCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the pure cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 40-83 CAG repeats, compared to 6-39 in the normal allele, and is associated with spinocerebellar ataxia type 1 (SCA1). At least two transcript variants encoding the same protein have been found for ATXN1 (ataxin 1).

The Phospho-Ataxin-1 (S776) Polyclonal Antibody is a highly specific and reliable tool designed for the detection and analysis of phosphorylated Ataxin-1 at serine 776 residue. Ataxin-1 is a protein involved in the pathogenesis of spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder characterized by progressive loss of motor coordination and balance. This antibody has been meticulously developed and validated to ensure exceptional sensitivity and specificity in recognizing the phosphorylated form of Ataxin-1 at serine 776.

The Phospho-Ataxin-1 (S776) Polyclonal Antibody exhibits outstanding performance in various applications, including Western blotting, immunoprecipitation, and immunofluorescence. It enables researchers to investigate the phosphorylation status of Ataxin-1 in different cellular and tissue samples, facilitating a deeper understanding of the molecular mechanisms underlying SCA1 and related disorders.

This antibody is produced using high-quality materials and state-of-the-art techniques, ensuring batch-to-batch consistency and reproducibility. It has been rigorously tested against a wide range of samples to guarantee its specificity and minimal cross-reactivity with non-phosphorylated Ataxin-1 or other proteins. The Phospho-Ataxin-1 (S776) Polyclonal Antibody offers exceptional sensitivity, allowing for the detection of even low levels of phosphorylated Ataxin-1.

With its superior performance and reliability, the Phospho-Ataxin-1 (S776) Polyclonal Antibody is an indispensable tool for researchers studying the role of Ataxin-1 phosphorylation in neurodegenerative diseases. Its precise targeting of the phosphorylated form of Ataxin-1 at serine 776 ensures accurate and reliable results, enabling researchers to advance their understanding of SCA1 and potentially contribute to the development of therapeutic interventions.